10-Q: Tempest Therapeutics Announces First Quarter 2025 Results and Strategic Review

Tempest Therapeutics reports Q1 2025 results, initiates strategic review, and reduces workforce amid going concern uncertainty.

Summary

• Tempest Therapeutics reported a net loss of $10.9 million for the three months ended March 31, 2025, compared to a net loss of $7.9 million for the same period in 2024.
• Research and development expenses increased to $7.6 million from $4.3 million year-over-year, primarily due to costs related to the pivotal Phase 3 trial preparation for amezalpat.
• General and administrative expenses decreased slightly to $3.3 million.
• The company's cash and cash equivalents decreased to $21.5 million as of March 31, 2025, from $30.3 million at the end of 2024.
• Tempest announced a strategic review to explore options for maximizing stockholder value, including potential mergers, acquisitions, or licensing arrangements.
• A reduction in force was implemented, affecting 21 of 26 full-time employees, expected to result in $1.5 million in cash expenditures.
• The company expects its existing cash and cash equivalents, along with $1.2 million from its ATM program, to fund operations for less than 12 months, raising substantial doubt about its ability to continue as a going concern.
• A one-for-thirteen reverse stock split was effected on April 8, 2025.
• The company repaid its loan with Oxford Finance LLC for $3.5 million on April 8, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the increased net loss, limited cash runway, strategic review indicating potential sale or restructuring, and workforce reduction. While there are some positive developments like FDA designations, the overall financial situation and strategic uncertainty weigh heavily.

Positives

• The FDA granted Fast Track Designation (FTD), underscoring the agency's recognition of the urgent need for new treatment options for HCC.
• The FDA granted Orphan Drug Designation (ODD) for amezalpat for the treatment of patients with HCC.
• The company has retained MTS Health Partners, L.P., an internationally recognized financial advisor with substantial experience in the biotechnology industry, to support it with the strategic evaluation process.
• The company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

Negatives

• The company's cash reserves stood at $21.5 million as of March 31, 2025, a decrease from $30.3 million at the end of 2024.
• The company expects its existing cash and cash equivalents, along with $1.2 million from its ATM program, to fund operations for less than 12 months, raising substantial doubt about its ability to continue as a going concern.
• The company has a history of operating losses, and may not achieve or sustain profitability.
• The company implemented a corporate restructuring plans designed to optimize its resource allocation and contain costs. In connection with the restructuring plan, the company reduced its workforce by 21 of 26 full-time employees, which was completed by the end of April 2025.

Risks

• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company will require substantial additional funding to finance its operations, which may not be available on acceptable terms or at all.
• The company's activities to evaluate and pursue potential strategic alternatives may not result in any transaction or enhance stockholder value.
• The company's recently implemented corporate restructuring intended to optimize its resource allocation and contain costs may not have the benefits the company expects.
• The company may not be successful in its efforts to expand its pipeline of product candidates and develop marketable products.
• The company may rely on third parties to manufacture its clinical product supplies, and the company may have to rely on third parties to produce and process its product candidates, if approved.
• The company faces significant competition in an environment of rapid technological change.
• The FDA regulatory approval process is lengthy and time-consuming, and the company may experience significant delays in the clinical development and regulatory approval of its product candidates.
• The trading price of the shares of the company's common stock has been and is likely to continue to be volatile, and purchasers of the company's common stock could incur substantial losses.
• The company's common stock is thinly traded and the company's stockholders may be unable to sell their shares quickly or at market price.

Future Outlook

The company is exploring strategic alternatives to maximize stockholder value and advance its clinical programs, while also implementing cost reductions. The company expects its existing cash and cash equivalents plus the net proceeds of $ 1.2 million from the Companys ATM Program will fund the Company's projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued.

Management Comments

• Given market conditions, in April 2025, we announced plans to explore a full range of strategic alternatives to advance our promising programs.
• We have not set a timetable for completion of the process for evaluating strategic alternatives and do not intend to disclose further developments or guidance on the status of its programs or the process for evaluating strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary.

Industry Context

The company operates in the competitive biotechnology industry, focusing on targeted and immune-mediated product candidates for cancer treatment. The strategic review and cost reduction efforts reflect the challenges faced by smaller biotech companies in securing funding and advancing clinical programs in the current market environment.

Comparison to Industry Standards

• Given the limited information, a direct comparison to industry standards is challenging.
• However, the company's cash runway and strategic review are common themes among smaller biotech firms facing funding constraints.
• Comparable companies in the oncology space often pursue partnerships or acquisitions to overcome resource limitations.
• The company's decision to reduce its workforce is also a typical response to conserve capital and extend its operational runway.

Stakeholder Impact

• Shareholders face uncertainty due to the strategic review and potential for dilution or loss of investment.
• Employees experienced job losses as part of the workforce reduction.
• Patients may experience delays in the development and availability of new cancer treatments.
• Suppliers and creditors may face increased risk due to the company's financial instability.

Next Steps

• Advance amezalpat into a pivotal Phase 3 study in first-line HCC patients.
• Explore TPST-1495 in a Phase 2 study in patients with FAP with the CP-CTNet in 2025.
• Explore strategic and business development opportunities to maximize the potential of our pipeline and extend financial resources.

Key Dates

Keywords

amezalpat, TPST-1495, strategic review, clinical trials, biotechnology, oncology, going concern, reverse stock split, financial results, research and development